{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:22:58Z","timestamp":1787844178805,"version":"build-2784847793"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To synthesize adverse event (AE) data from randomized controlled trials (RCTs) of levetiracetam (LEV) and brivaracetam (BRV), compare their safety profiles, and identify moderators of AE risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of RCTs of LEV or BRV, searching PubMed, Web of Science, and ClinicalTrials.gov to August 2025. AE frequencies were summarized qualitatively, and random-effects meta-analyses compared LEV and BRV with placebo. Additional analyses compared LEV and BRV and assessed moderators. PROSPERO: CRD42023491050, CRD420251003207.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-six RCTs including 7145 patients exposed to LEV and 2549 to BRV were analyzed. Qualitative synthesis identified headache, somnolence, dizziness, and fatigue as the most common AEs, with higher frequencies of some psychiatric AEs (e.g., irritability, aggression) reported for LEV. Meta-analyses showed increased somnolence with both LEV (OR 1.80, 95% CI [1.41\u20132.30]) and BRV (OR 1.86, 95% CI [1.33\u20132.61]). LEV was additionally associated with irritability (OR 2.55, 95% CI [1.41\u20134.63]) and asthenia (OR 1.71, 95% CI [1.15\u20132.54]), whereas BRV was associated with dizziness (OR 1.75, 95% CI [1.24\u20132.46]) and fatigue (OR 2.14, 95% CI [1.43\u20133.20]). Few moderators of AE risk were identified, and no significant differences emerged between LEV and BRV in indirect comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LEV and BRV show favorable safety profiles that appear comparable based on meta-analytic findings, despite higher rates of some psychiatric AEs with LEV on a descriptive level. Both remain safe treatment options, though larger head-to-head trials are needed to provide definitive comparative evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13746-9","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:20:24Z","timestamp":1773393624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reassessing the adverse event profiles of levetiracetam and brivaracetam: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6501-3361","authenticated-orcid":false,"given":"Emma","family":"Fr\u00f6ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8880-0380","authenticated-orcid":false,"given":"Mariel","family":"Morales Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7519-1724","authenticated-orcid":false,"given":"Marcel","family":"Schmude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte P.","family":"Assies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-1856","authenticated-orcid":false,"given":"Michael","family":"Wittenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-7471","authenticated-orcid":false,"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3260-6328","authenticated-orcid":false,"given":"Felix","family":"Bermpohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-3192","authenticated-orcid":false,"given":"Thomas G.","family":"Riemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"13746_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM (2022) Antiseizure medications for adults with epilepsy: a review. JAMA 327:1269\u20131281. https:\/\/doi.org\/10.1001\/jama.2022.3880","journal-title":"JAMA"},{"key":"13746_CR2","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","volume":"10","author":"Collaborators GBDE","year":"2025","unstructured":"Collaborators GBDE (2025) Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health 10:e203\u2013e227. https:\/\/doi.org\/10.1016\/S2468-2667(24)00302-5","journal-title":"Lancet Public Health"},{"key":"13746_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106856","volume":"104","author":"JM Welton","year":"2020","unstructured":"Welton JM, Walker C, Riney K, Ng A, Todd L, D\u2019Souza WJ (2020) Quality of life and its association with comorbidities and adverse events from antiepileptic medications: online survey of patients with epilepsy in Australia. Epilepsy Behav 104:106856. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106856","journal-title":"Epilepsy Behav"},{"key":"13746_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG (2012) Adverse effects of antiepileptic drugs. Lancet Neurol 11:792\u2013802. https:\/\/doi.org\/10.1016\/S1474-4422(12)70153-9","journal-title":"Lancet Neurol"},{"key":"13746_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/epi4.12967","volume":"9","author":"J Mao","year":"2024","unstructured":"Mao J, Takahashi K, Cheng M, Xu C, Boca A, Song Y, Dandurand A (2024) Real-world anti-seizure treatment and adverse events among individuals living with drug-resistant focal epilepsy in the United States. Epilepsia Open 9:1311\u20131320. https:\/\/doi.org\/10.1002\/epi4.12967","journal-title":"Epilepsia Open"},{"key":"13746_CR6","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/epi.13853","volume":"58","author":"G Giussani","year":"2017","unstructured":"Giussani G, Bianchi E, Canelli V, Erba G, Franchi C, Nobili A, Sander JW, Beghi E (2017) Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia 58:1524\u20131532. https:\/\/doi.org\/10.1111\/epi.13853","journal-title":"Epilepsia"},{"key":"13746_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/ane.13312","volume":"142","author":"M Compagno Strandberg","year":"2020","unstructured":"Compagno Strandberg M, Soderberg-Lofdal K, Kimland E, Dahlin M, Kallen K (2020) Evidence-based anti-seizure monotherapy in newly diagnosed epilepsy: a new approach. Acta Neurol Scand 142:323\u2013332. https:\/\/doi.org\/10.1111\/ane.13312","journal-title":"Acta Neurol Scand"},{"key":"13746_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00192","volume":"4","author":"C Wright","year":"2013","unstructured":"Wright C, Downing J, Mungall D, Khan O, Williams A, Fonkem E, Garrett D, Aceves J, Kirmani B (2013) Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol 4:192. https:\/\/doi.org\/10.3389\/fneur.2013.00192","journal-title":"Front Neurol"},{"key":"13746_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000209821","volume":"103","author":"SN Barnard","year":"2024","unstructured":"Barnard SN, Chen Z, Kanner AM, Holmes MG, Klein P, Abou-Khalil BW, Gidal BE, French J, Perucca P (2024) The adverse effects of commonly prescribed antiseizure medications in adults with newly diagnosed focal epilepsy. Neurology 103:e209821. https:\/\/doi.org\/10.1212\/wnl.0000000000209821","journal-title":"Neurology"},{"key":"13746_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5586","volume":"10","author":"JF Zhang","year":"2022","unstructured":"Zhang JF, Piryani R, Swayampakula AK, Farooq O (2022) Levetiracetam-induced aggression and acute behavioral changes: a case report and literature review. Clin Case Rep 10:e05586. https:\/\/doi.org\/10.1002\/ccr3.5586","journal-title":"Clin Case Rep"},{"key":"13746_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","volume":"31","author":"A Verrotti","year":"2015","unstructured":"Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G (2015) The adverse event profile of levetiracetam: a meta-analysis on children and adults. Seizure 31:49\u201355. https:\/\/doi.org\/10.1016\/j.seizure.2015.07.004","journal-title":"Seizure"},{"key":"13746_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","volume":"664","author":"M Gillard","year":"2011","unstructured":"Gillard M, Fuks B, Leclercq K, Matagne A (2011) Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 664:36\u201344. https:\/\/doi.org\/10.1016\/j.ejphar.2011.04.064","journal-title":"Eur J Pharmacol"},{"key":"13746_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.14581\/jer.25005","volume":"15","author":"H Hwang","year":"2025","unstructured":"Hwang H, Kim WJ (2025) Brivaracetam: pharmacology, clinical efficacy, and safety in epilepsy. J Epilepsy Res 15:42\u201355. https:\/\/doi.org\/10.14581\/jer.25005","journal-title":"J Epilepsy Res"},{"key":"13746_CR14","unstructured":"NICE (2025) Epilepsies in children, young people and adults. https:\/\/www.nice.org.uk\/guidance\/ng217\/resources\/epilepsies-in-children-young-people-and-adults-pdf-66143780239813. Accessed 16 Aug 2025"},{"key":"13746_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.seizure.2016.11.008","volume":"45","author":"LN Zhu","year":"2017","unstructured":"Zhu LN, Chen D, Chen T, Xu D, Chen SH, Liu L (2017) The adverse event profile of brivaracetam: a meta-analysis of randomized controlled trials. Seizure 45:7\u201316. https:\/\/doi.org\/10.1016\/j.seizure.2016.11.008","journal-title":"Seizure"},{"key":"13746_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106657","volume":"102","author":"E Fonseca","year":"2020","unstructured":"Fonseca E, Guzman L, Quintana M, Abraira L, Santamarina E, Salas-Puig X, Toledo M (2020) Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. Epilepsy Behav 102:106657. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106657","journal-title":"Epilepsy Behav"},{"key":"13746_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.seizure.2016.05.004","volume":"39","author":"L Zhang","year":"2016","unstructured":"Zhang L, Li S, Li H, Zou X (2016) Levetiracetam vs. brivaracetam for adults with refractory focal seizures: a meta-analysis and indirect comparison. Seizure 39:28\u201333. https:\/\/doi.org\/10.1016\/j.seizure.2016.05.004","journal-title":"Seizure"},{"key":"13746_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/epi.13267","volume":"57","author":"JM Nicolas","year":"2016","unstructured":"Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57:201\u2013209. https:\/\/doi.org\/10.1111\/epi.13267","journal-title":"Epilepsia"},{"key":"13746_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/epi.13638","volume":"58","author":"MD Wood","year":"2017","unstructured":"Wood MD, Gillard M (2017) Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia 58:255\u2013262. https:\/\/doi.org\/10.1111\/epi.13638","journal-title":"Epilepsia"},{"key":"13746_CR20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s12264-023-01138-2","volume":"40","author":"PP Wu","year":"2024","unstructured":"Wu PP, Cao BR, Tian FY, Gao ZB (2024) Development of SV2A ligands for epilepsy treatment: a review of levetiracetam, brivaracetam, and padsevonil. Neurosci Bull 40:594\u2013608. https:\/\/doi.org\/10.1007\/s12264-023-01138-2","journal-title":"Neurosci Bull"},{"key":"13746_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107939","volume":"118","author":"BJ Steinhoff","year":"2021","unstructured":"Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti-Masterson K, Rosenow F, Sirven JI, Smith B, Stern JM, Toledo M, Zipfel PA, Villanueva V (2021) Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav 118:107939. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107939","journal-title":"Epilepsy Behav"},{"key":"13746_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1170780","volume":"14","author":"T Song","year":"2023","unstructured":"Song T, Feng L, Xia Y, Pang M, Geng J, Zhang X, Wang Y (2023) Safety and efficacy of brivaracetam in children epilepsy: a systematic review and meta-analysis. Front Neurol 14:1170780. https:\/\/doi.org\/10.3389\/fneur.2023.1170780","journal-title":"Front Neurol"},{"key":"13746_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"13746_CR24","unstructured":"(MSSO) MMaSSO (2024) Introductory guide to MedDRA version 27.0. https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_27_0.pdf. Accessed 16 Aug 2025"},{"key":"13746_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan M, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"13746_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1161\/HYPERTENSIONAHA.120.16590","volume":"77","author":"TG Riemer","year":"2021","unstructured":"Riemer TG, Villagomez Fuentes LE, Algharably EAE, Schafer MS, Mangelsen E, Furtig MA, Bittner N, Bar A, Zaidi Touis L, Wachtell K, Majic T, Dinges MJ, Kreutz R (2021) Do beta-blockers cause depression?: Systematic review and meta-analysis of psychiatric adverse events during beta-blocker therapy. Hypertension 77:1539\u20131548. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16590","journal-title":"Hypertension"},{"key":"13746_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jrsm.1240","volume":"8","author":"D Jackson","year":"2017","unstructured":"Jackson D, Turner R (2017) Power analysis for random-effects meta-analysis. Res Synth Methods 8:290\u2013302. https:\/\/doi.org\/10.1002\/jrsm.1240","journal-title":"Res Synth Methods"},{"key":"13746_CR28","unstructured":"Collaboration TC (2025) Review manager (RevMan) [Computer program]. Version 9.5.2. In: The Cochrane Collaboration"},{"key":"13746_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jclinepi.2020.08.019","volume":"142","author":"SA Doi","year":"2022","unstructured":"Doi SA, Furuya-Kanamori L, Xu C, Lin L, Chivese T, Thalib L (2022) Controversy and debate: questionable utility of the relative risk in clinical research: Paper 1: a call for change to practice. J Clin Epidemiol 142:271\u2013279. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.08.019","journal-title":"J Clin Epidemiol"},{"key":"13746_CR30","unstructured":"Deeks JJ, Higgins JPT, Altman DG, McKenzie JE, Veroniki AA. (2024) Chapter 10: analysing data and undertaking meta-analyses [last updated november 2024]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed) Cochrane handbook for systematic reviews of interventions, version 6.5. Cochrane"},{"key":"13746_CR31","unstructured":"Team RC (2025) R: a language and environment for statistical computing. In: R Foundation for Statistical Computing, Vienna, Austria"},{"key":"13746_CR32","unstructured":"Viechtbauer W (2025) metafor: Meta-analysis package for R, Version: 4.8\u20130. In: CRAN"},{"key":"13746_CR33","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1055\/s-0044-1790516","volume":"19","author":"R Pandya","year":"2024","unstructured":"Pandya R, Sundaram PK, Baghel SS (2024) Comparison of effectiveness of brivaracetam and levetiracetam for prophylaxis of early post-traumatic seizures: a prospective comparative interventional study. Asian J Neurosurg 19:728\u2013734. https:\/\/doi.org\/10.1055\/s-0044-1790516","journal-title":"Asian J Neurosurg"},{"key":"13746_CR34","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/ane.13059","volume":"139","author":"V Villanueva","year":"2019","unstructured":"Villanueva V, Lopez-Gonzalez FJ, Mauri JA, Rodriguez-Uranga J, Olive-Gadea M, Montoya J, Ruiz-Gimenez J, Zurita J, group B-Ls (2019) BRIVA-LIFE-a multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand 139:360\u2013368. https:\/\/doi.org\/10.1111\/ane.13059","journal-title":"Acta Neurol Scand"},{"key":"13746_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.seizure.2017.07.017","volume":"51","author":"LN Zhu","year":"2017","unstructured":"Zhu LN, Chen D, Xu D, Tan G, Wang HJ, Liu L (2017) Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: an indirect comparison. Seizure 51:121\u2013132. https:\/\/doi.org\/10.1016\/j.seizure.2017.07.017","journal-title":"Seizure"},{"key":"13746_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.7326\/0003-4819-144-4-200602210-00007","volume":"144","author":"S Bent","year":"2006","unstructured":"Bent S, Padula A, Avins AL (2006) Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 144:257\u2013261. https:\/\/doi.org\/10.7326\/0003-4819-144-4-200602210-00007","journal-title":"Ann Intern Med"},{"key":"13746_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-15224-6","volume-title":"Evidence-based practice in clinical social work","author":"JW Drisko","year":"2019","unstructured":"Drisko JW, Grady MD (2019) Step 3 of EBP: part 1\u2014evaluating research designs. Evidence-based practice in clinical social work. Springer"},{"key":"13746_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","volume":"2","author":"A Lundh","year":"2017","unstructured":"Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2:MR000033. https:\/\/doi.org\/10.1002\/14651858.MR000033.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"13746_CR39","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1002\/sim.6525","volume":"34","author":"M Kicinski","year":"2015","unstructured":"Kicinski M, Springate DA, Kontopantelis E (2015) Publication bias in meta-analyses from the cochrane database of systematic reviews. Stat Med 34:2781\u20132793. https:\/\/doi.org\/10.1002\/sim.6525","journal-title":"Stat Med"},{"key":"13746_CR40","unstructured":"Peryer G, Golder S, Junqueira D, Vohra S, Loke YK (2024) Chapter 19: adverse effects [last updated october 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed) Cochrane handbook for systematic reviews of interventions, version 6.5. Cochrane"},{"key":"13746_CR41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.yebeh.2008.01.008","volume":"13","author":"GM Filho","year":"2008","unstructured":"Filho GM, Rosa VP, Lin K, Caboclo LO, Sakamoto AC, Yacubian EM (2008) Psychiatric comorbidity in epilepsy: a study comparing patients with mesial temporal sclerosis and juvenile myoclonic epilepsy. Epilepsy Behav 13:196\u2013201. https:\/\/doi.org\/10.1016\/j.yebeh.2008.01.008","journal-title":"Epilepsy Behav"},{"key":"13746_CR42","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10341","volume":"22","author":"RS Gurgu","year":"2021","unstructured":"Gurgu RS, Ciobanu AM, Danasel RI, Panea CA (2021) Psychiatric comorbidities in adult patients with epilepsy (a systematic review). Exp Ther Med 22:909. https:\/\/doi.org\/10.3892\/etm.2021.10341","journal-title":"Exp Ther Med"},{"key":"13746_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/acn3.51255","volume":"8","author":"A Shakeshaft","year":"2021","unstructured":"Shakeshaft A, Panjwani N, McDowall R, Crudgington H, Pena Ceballos J, Andrade DM, Beier CP, Fong CY, Gesche J, Greenberg DA, Hamandi K, Koht J, Lim KS, Orsini A, Rees MI, Rubboli G, Selmer KK, Smith AB, Striano P, Syvertsen M, Talvik I, Thomas RH, Zarubova J, Richardson MP, Strug LJ, Pal DK, Consortium B (2021) Trait impulsivity in Juvenile myoclonic epilepsy. Ann Clin Transl Neurol 8:138\u2013152. https:\/\/doi.org\/10.1002\/acn3.51255","journal-title":"Ann Clin Transl Neurol"},{"key":"13746_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1528-1167.2012.03603.x","volume":"54","author":"C Helmstaedter","year":"2013","unstructured":"Helmstaedter C, Mihov Y, Toliat MR, Thiele H, Nuernberg P, Schoch S, Surges R, Elger CE, Kunz WS, Hurlemann R (2013) Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia 54:36\u201344. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03603.x","journal-title":"Epilepsia"},{"key":"13746_CR45","unstructured":"Dean L (2012) Brivaracetam therapy and CYP2C19 genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ (eds), Medical genetics summaries"},{"key":"13746_CR46","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/epi.13859","volume":"58","author":"JM Pellock","year":"2017","unstructured":"Pellock JM, Arzimanoglou A, D\u2019Cruz O, Holmes GL, Nordli D, Shinnar S, Pediatric Epilepsy Academic Consortium for E (2017) Extrapolating evidence of antiepileptic drug efficacy in adults to children >\/=2 years of age with focal seizures: the case for disease similarity. Epilepsia 58:1686\u20131696. https:\/\/doi.org\/10.1111\/epi.13859","journal-title":"Epilepsia"},{"key":"13746_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/phar.2760","volume":"43","author":"M Strein","year":"2023","unstructured":"Strein M, Holton-Burke JP, Stilianoudakis S, Moses C, Almohaish S, Brophy GM (2023) Levetiracetam-associated behavioral adverse events in neurocritical care patients. Pharmacotherapy 43:122\u2013128. https:\/\/doi.org\/10.1002\/phar.2760","journal-title":"Pharmacotherapy"},{"key":"13746_CR48","unstructured":"(WHO) WHO (2023) Antiseizure medicines for management of epilepsy in adults and children. World Health Organization. https:\/\/www.who.int\/teams\/mental-health-and-substance-use\/treatment-care\/mental-health-gap-action-programme\/evidence-centre\/epilepsy-and-seizures\/antiseizure-medicines-for-management-of-epilepsy-in-adults-and-children. Accessed 29 Jul 2025"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13746-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:55:05Z","timestamp":1785830105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13746-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["13746"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13746-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to retrospective open access order.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FR has received honoraria for lecturing and consultation from Angelini Pharma, Eisai GmbH, Jazz Pharma, Roche Pharma, Stoke Therapeutics, Takeda, and UCB Pharma, and has received financial research support from Dr. Sch\u00e4r Deutschland GmbH, Vitaflo Deutschland GmbH, Nutricia Milupa GmbH, Desitin Pharma, Hamburg, Federal State of Hessen (via the LOEWE-Programme), Chaja Foundation Frankfurt, Reiss Foundation Frankfurt, Dr. Senckenbergische Foundation Frankfurt, Ernst Max von Grunelius Foundation Frankfurt, and Detlev-Wrobel Fonds for Epilepsy Research Frankfurt, outside the submitted work. The remaining authors declare that they have no conflict of interest. EF and MMS are employees of Pfizer Pharma GmbH. This research was conducted independently and was not influenced by their employment. The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Registered in PROSPERO: CRD42023491050 (6.12.2023) and CRD420251003207 (3.3.2025).","order":2,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"204"}}